Exagamglogene autotemcel is under clinical development by CRISPR Therapeutics and currently in Phase III for Sickle Cell Disease. According to GlobalData, Phase III drugs for Sickle Cell Disease have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Exagamglogene autotemcel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Exagamglogene autotemcel overview

Exagamglogene autotemcel (Casgevy) is a genetically modified autologous CD34+
cell enriched population that contains human hematopoietic stem and progenitor
cells edited ex vivo by CRISPR/Cas9 at the erythroid-specific enhancer region of the BCL11A gene. It is formulated as suspension for intravenous route of administration. Casgevy is indicated for the treatment of transfusion-dependent β-thalassemia and also for the treatment of sickle cell disease in patients 12 years of age and older with recurrent vaso occlusive crises who have the βS/βS, βS/β+ or βS/β0 genotype in patients 12 years of age and older for whom hematopoietic stem cell transplantation is appropriate and a human leukocyte antigen matched related hematopoietic stem cell donor is not available.
Exagamglogene autotemcel (CTX-001) is under development for the treatment of sickle cell disease and beta-thalassemia. The therapeutic candidate constitutes of ex vivo corrected CD34 positive hematopoietic stem and progenitor cells (HSPCs). It is administered through the intravenous route and is developed based on CRISPR/Cas9 gene-editing technology.

CRISPR Therapeutics overview

CRISPR Therapeutics (CRISPR) is a gene editing company. It focuses on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a gene-editing technology that modifies, deletes, or corrects disease-causing abnormalities at its genetic sources. Its major development programs include ex vivo programs involving gene editing of hematopoietic cells; ex vivo programs in immuno-oncology; in vivo programs targeting the liver and additional in vivo programs targeting other organ systems including muscle and lung. It has research and development operations in Cambridge, Massachusetts, the US and business operations in London, the UK. CRISPR is headquartered in Zug, Switzerland.

For a complete picture of Exagamglogene autotemcel’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.